Calliditas Therapeutics
Calliditas Therapeutics: Our Comment on the Capital Raise (Redeye)
2020-06-23 07:20
Redeye maintains its positive view and Base case of SEK 140 following Calliditas’ US IPO and concurrent private placement.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se